Tiamat Sciences cooking up plant-based proteins for cheaper production of cellular meat

DMCA / Correction Notice
- Advertisement -


Cellular growth medium is a component of cellular agriculture that enables lab-grown meats to be produced at low cost. However, the traditional methods of making these growth factors, or reagents themselves, are expensive, making large-scale manufacturing difficult.

- Advertisement -

On average, reports show that Lab grown meat costs around $50 . Is, but that new technologies may make it more reasonable $3 per pound by 2030,

tiamat science is a biotech startup developing more cost-effective biomolecules that aims to replace more expensive bioreactors. Today, it announced $3 million in seed funding, led by True Ventures, with participation from Social Impact Capital and Cantos.

advertisement

France-Emmanuel Adil, Founder and CEO, Tiamet Sciences. image credit: Tiamat Science

The company’s CEO, France-Emmanuel Adil, founded the company in 2019 to manufacture animal-free proteins using a proprietary plant molecular farming approach that combines biotechnology, vertical farming and The calculation combines the design.

- Advertisement -

“The growth factors used in the media are expensive right now,” she told Nerdshala. “We can drastically reduce costs and reach price parity with meat.”

Adil estimates that today’s growth factor costs $2 million per gram to make, but he believes that with the efforts of Tiamat Science and others, the focus will be on making it 1,000 times cheaper by 2025. With this the cost can be reduced by 10 times so that mass production can go ahead.

Prior to the $3 million seed round, the company raised a smaller round last July, giving it $3.4 million in total funding to date. Adil wanted to expand the company, which was in Belgium, where it has an operating site, and moved to North Carolina in May.

The new funding will support a pilot production facility and technology development in Durham, North Carolina. The company is already on track to reach carbon-neutral production.

She wasn’t able to disclose customers yet, but said the company is in development for its first product with the aim of releasing by the end of the year. Tiamat will then send samples to customers for testing, which they believe will lead to some partnership in 2022.

In addition to food, Adil says Tiamat’s approach could be applicable in other industries such as regenerative medicine and vaccine production.

“The growth factors are transferable to other industries because the processes are similar,” she said. “We will be working on expansion by the end of 2022. We will expand very rapidly with several plants and then 100,000 plants. We are in discussions with companies to help on a large scale but progressively.”

True Ventures co-founder Phil Black said the investment in Tiamat Sciences fits into its plant-based portfolio. The initial funding the company raised allows them to prove to people that their technology works and produce it at a trial stage. Then there will be a huge round on the scale from liters to gallons.

“The cell meat industry is here to stay and now people are interested in making it more profitable for themselves and making more of it,” he said. “Limiting factors exist, and Taimat’s solution will be a game-changer.”

- Advertisement -

Stay on top - Get the daily news in your inbox

Recent Articles

Related Stories